Difficulty in treating older hepatitis C patients with combination (Chronic Hepatitis C)

Difficulty in treating older hepatitis C patients with combination
EurekAlert - A new study in Japan examining the effects of combination therapy on older patients with hepatitis C found more adverse effects necessitating discontinuation of treatment, lowering of dosages, and lower long-term benefits in this age group. The

Diazyme Receives FDA 510(K) Approval for Enzymatic Total Bile Acids
Market Wire - SAN DIEGO, CA -- (MARKET WIRE) -- 12/22/2005 -- Diazyme Laboratories, a company that applies its proprietary enzyme technologies to develop low cost and high quality diagnostic products for clinical and research uses, announced today that the U.S

What's New in Hepatitis C: Current State of the Field and Future
Medscape News - The current standard of care for the treatment of previously untreated patients with chronic hepatitis C is a combination of once-weekly injection of pegylated interferon plus daily oral ribavirin. The treatment duration is dependent on HCV genotype

Valeant Pharmaceuticals Completes Acquisition of Hep-C Drug Infergen
dBusinessNews.com - Orange County: Toshiba Announces Satellite A105 Notebook Series with New Styling IRVINE -- Toshiba's Digital Products Division, a division of Toshiba Orange County: Valeant Pharmaceuticals Completes Acquisition of Hep-C Drug Infergen From